Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905879965> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2905879965 endingPage "S294" @default.
- W2905879965 startingPage "S294" @default.
- W2905879965 abstract "To estimate, from Colombian health system perspective the cost–effectiveness of etanercept as first line of treatment for ankylosing spondylitis (AS) A Markov model was developed to determine the quality-adjusted life-years (QALYs) of four treatments as first line of treatment of AS: etanercept (50 mg once weekly); infliximab (infusion of 5 mg/kg at weeks 0, 2, 6 and 14), golimumab (50 mg every 4 weeks), adalimumab (40 mg every other week). Other treatments were not included due to lack of randomized controlled trials (RCTs) in this line of treatment. The efficacy and safety were taken from published studies. Bayesian mixed treatment comparison method was applied for the indirect comparison of treatments. The cost of the drugs, cost of health care services according to level of bath ankylosing spondylitis functional index (BASFI) were estimated using official tariffs and databases from Colombia. The time horizon was 20 years. An annual discounted rate of 5% was applied. All currency units are in USD$ (1 USD$ = COP 2,951.15). We used as threshold for Colombia three times the GDP per capita (USD$ 18,819). Results were tested using deterministic and probabilistic sensitivity analyses. The total expected costs per patient were etanercept USD$ 28,240.27 ; adalimumab USD$ 29.901,74 ; infliximab USD$ 30,214.88 ; and golimumab USD$ 32,228.72. The results in terms of QALYs were etanercept (9.08); adalimumab (9.04); infliximab (9.23) and golimumab (9.11). Adalimumab and golimumab were dominated by etanercept. The ICER of etanercept compared to infliximab was USD$ 13,558.49 per QALY. The results were sensible by horizon time. The analysis suggests that etanercept is a cost-effectiveness treatment as first –line treatment for AS in Colombia. Considering that the minimum difference in terms of QALYs, the lowest cost of treatment would be the main determinant into decision making." @default.
- W2905879965 created "2019-01-01" @default.
- W2905879965 creator A5011946740 @default.
- W2905879965 creator A5028323021 @default.
- W2905879965 creator A5057154255 @default.
- W2905879965 date "2018-10-01" @default.
- W2905879965 modified "2023-10-18" @default.
- W2905879965 title "PMS40 - COST – EFFECTIVENESS STUDY OF ETANERCEPT AS FIRST LINE TREATMENT FOR ANKYLOSING SPONDYLITIS IN COLOMBIA" @default.
- W2905879965 doi "https://doi.org/10.1016/j.jval.2018.09.1754" @default.
- W2905879965 hasPublicationYear "2018" @default.
- W2905879965 type Work @default.
- W2905879965 sameAs 2905879965 @default.
- W2905879965 citedByCount "0" @default.
- W2905879965 crossrefType "journal-article" @default.
- W2905879965 hasAuthorship W2905879965A5011946740 @default.
- W2905879965 hasAuthorship W2905879965A5028323021 @default.
- W2905879965 hasAuthorship W2905879965A5057154255 @default.
- W2905879965 hasBestOaLocation W29058799651 @default.
- W2905879965 hasConcept C126322002 @default.
- W2905879965 hasConcept C17991360 @default.
- W2905879965 hasConcept C2777138892 @default.
- W2905879965 hasConcept C2777226972 @default.
- W2905879965 hasConcept C2777402515 @default.
- W2905879965 hasConcept C2780132546 @default.
- W2905879965 hasConcept C2781290027 @default.
- W2905879965 hasConcept C71924100 @default.
- W2905879965 hasConceptScore W2905879965C126322002 @default.
- W2905879965 hasConceptScore W2905879965C17991360 @default.
- W2905879965 hasConceptScore W2905879965C2777138892 @default.
- W2905879965 hasConceptScore W2905879965C2777226972 @default.
- W2905879965 hasConceptScore W2905879965C2777402515 @default.
- W2905879965 hasConceptScore W2905879965C2780132546 @default.
- W2905879965 hasConceptScore W2905879965C2781290027 @default.
- W2905879965 hasConceptScore W2905879965C71924100 @default.
- W2905879965 hasLocation W29058799651 @default.
- W2905879965 hasOpenAccess W2905879965 @default.
- W2905879965 hasPrimaryLocation W29058799651 @default.
- W2905879965 hasRelatedWork W2050121444 @default.
- W2905879965 hasRelatedWork W2137530185 @default.
- W2905879965 hasRelatedWork W2314016917 @default.
- W2905879965 hasRelatedWork W2320241810 @default.
- W2905879965 hasRelatedWork W2327054863 @default.
- W2905879965 hasRelatedWork W2332840597 @default.
- W2905879965 hasRelatedWork W2408908265 @default.
- W2905879965 hasRelatedWork W2898641256 @default.
- W2905879965 hasRelatedWork W4283710071 @default.
- W2905879965 hasRelatedWork W4321375011 @default.
- W2905879965 hasVolume "21" @default.
- W2905879965 isParatext "false" @default.
- W2905879965 isRetracted "false" @default.
- W2905879965 magId "2905879965" @default.
- W2905879965 workType "article" @default.